RxDoctor Payments Data

Pan Ko, MD

Infectious Disease · Englewood Cliffs, NJNPI 1083851687

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,990 of the $15,617 with a category attached, or 64.0%. 27 manufacturers reported payments, led by AbbVie at 41.2% of the total. Reporting peaked in 2019 at $4,180 and has fallen 60.1% since, to $1,666 in 2025. Among infectious disease clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,617in general payments, 2019–2025

Across 482 payments — averaging $32.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Gilead$3K
  • Viiv Healthcare Company$1K
  • Smith+Nephew$723
  • Insmed, Inc.$618
  • Organogenesis Inc.$548
  • plus $3K from 21 others

What the payments were for

  • Consulting fees$3002%
  • Speaking & faculty fees$4,20027%
  • Travel & lodging$8405%
  • Food & beverage$9,99064%
  • Education$2862%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,617 in reported general payments places this provider in the 90th percentile of 334 infectious disease providers in New Jersey.

See all infectious disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$355,806
Medicare patients
644
Services billed
6,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArikayceAmikacin Liposomal/Neb.Accessr16$241,233
BiktarvyBictegrav/Emtricit/Tenofov Ala26$126,218
DovatoDolutegravir Sodium/Lamivudine25$74,962
TriumeqAbacavir/Dolutegravir/Lamivudi12$50,480
JulucaDolutegravir/Rilpivirine12$48,530
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf11$48,448
Isentress HdRaltegravir Potassium14$38,133
CeftriaxoneCeftriaxone Sodium52$7,195
Methenamine Hippurate53$5,292
Vancomycin Hcl40$4,559
Linezolid14$2,074
Cephalexin36$1,395
Doxycycline Hyclate69$1,358
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$596
Fluconazole28$572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Insmed, Inc.Arikayce$618$241,23316 claims
Viiv Healthcare CompanyDovato, Triumeq, Juluca$1,143$173,97349 claims
GileadBiktarvy$2,884$126,21826 claims
Janssen Products, LPSymtuza$130$48,44811 claims
MerckIsentress Hd$406$38,13314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 334 infectious disease providers in New Jersey.

Other infectious disease in Englewood Cliffs

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →